Announcements Trials
Browse Landscape

Phase

Phase 2 78Phase 3 27Phase NA 7Phase 4 6Phase 2/3 5Phase 1/2 5Phase 1 5Phase EARLY_PHASE1 3

Status

Completed 40Recruiting 25Terminated 19Active not recruiting 11Unknown 5Not yet recruiting 4Withdrawn 3

Sponsor Class

OTHER 2UNKNOWN 1NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1Carcinoma, Squamous Cell 1Advanced Solid Tumor 1Adenocarcinoma 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 27Cisplatin 27Carboplatin 27Capecitabine 27camrelizumab 24Nivolumab 23apatinib 22Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 17Immunotherapy, Adoptive 17Drug Therapy 17pembrolizumab 16Docetaxel 16Dexamethasone 15Bevacizumab 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12130-nm albumin-bound paclitaxel 11anlotinib 10Fluorouracil 10Trastuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Pemetrexed × Clear all
NCT05794477 2023-06-02

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1/2 Unknown
132 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03706287 2020-04-06

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 1/2 Unknown
62 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

NCT03201146 2017-11-17

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

West China Hospital

Phase 1/2 Unknown
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00516100 2010-01-15

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Aptium Oncology Research Network

Phase 1/2 Unknown
62 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡